FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Described is a pharmaceutical composition for treating angiogenic diseases, comprising an antibody, which binds with VEGF, in an arginine acetate buffer, pH 4.5–6.0, and a surfactant, where antibody is bevacizumab.
EFFECT: invention enables to obtain a stable aqueous pharmaceutical composition containing a therapeutically effective amount of an antibody.
70 cl, 4 dwg, 8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS WITH REDUCED OXIDATION | 2014 |
|
RU2707092C2 |
| RECOMBINANT MONOCLONAL ANTIBODY TO TNF-ALPHA AQUEOUS PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2665966C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNF-α | 2017 |
|
RU2764521C2 |
| COMPOSITIONS WITH REDUCED OXIDATION | 2014 |
|
RU2707550C2 |
| IMPROVED PROTEIN PURIFICATION BY MEANS OF MODIFIED ELUATING OF PROTEIN A | 2010 |
|
RU2571929C2 |
| COMPOSITIONS OF ANTIBODIES | 2014 |
|
RU2694055C2 |
| PRECIPITATING AND PURIFYING PROTEINS WITH POLYELECTROLYTES | 2008 |
|
RU2474585C2 |
| METHOD OF EXTRACTING REFOLDED RECOMBINANT PROTEIN FROM PROKARYOTIC CELL CULTURE (VERSIONS) | 2007 |
|
RU2439076C2 |
| HIGHLY CONCENTRATED COMPOSITIONS OF ANTIBODIES AND PROTEINS | 2004 |
|
RU2332986C2 |
| COMPOSITION CONTAINING ANTIBODY | 2019 |
|
RU2806628C2 |
